Orkla ASA (OSL:ORK)
Norway
· Delayed Price · Currency is NOK | Market Cap | 110.83B |
| Revenue (ttm) | 71.55B |
| Net Income (ttm) | 11.47B |
| Shares Out | 981.66M |
| EPS (ttm) | 11.48 |
| PE Ratio | 17.76 |
| Forward PE | 16.79 |
| Dividend | 6.00 (5.31%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | 1,060,407 |
| Average Volume | 1,138,056 |
| Open | 113.10 |
| Previous Close | 113.00 |
| Day's Range | 112.50 - 113.60 |
| 52-Week Range | 100.60 - 131.20 |
| Beta | 0.26 |
| RSI | 27.21 |
| Earnings Date | May 20, 2026 |
About Orkla ASA
Orkla ASA operates as an industrial investment company within brands and consumer-oriented businesses worldwide. It offers decorative paints, marine coatings, protective coatings, and powder coatings; frozen pizza, condiments, bread toppings, and ready-to-eat meals; bakery, ice cream, and plant-based products; and confectionery, biscuits, and salty snacks. The company also provides branded consumer health products, such as daily nutrition and oral health, wound care, and functional personal care under the Möller’s, Jordan, and Salvequick brand ... [Read more]
Financial Performance
In 2025, Orkla ASA's revenue was 71.55 billion, an increase of 3.31% compared to the previous year's 69.25 billion. Earnings were 11.47 billion, an increase of 89.42%.
Financial StatementsNews
Orkla ASA Transcript: AGM 2026
The AGM reviewed strong 2025 financial results, approved a NOK 6 per share dividend, and passed all board proposals, including capital reduction and auditor change. Strategic focus remains on growth, portfolio simplification, and sustainability, with new board members elected and a shareholder proposal on plastic waste rejected.
Orkla ASA Earnings Call Transcript: Q4 2025
Q4 saw 4.5% organic growth and 17% EBIT adjusted increase, with all major segments except Foods contributing positively. Jotun and Orkla Snacks delivered strong profit growth, while inflation and competitive pressures remain key risks.
Orkla ASA Earnings Call Transcript: Q3 2025
Q3 saw 4.4% organic growth, 9% EPS increase, and NOK 17.9B revenue. Portfolio companies showed mixed performance, with Jotun and Orkla India as key contributors. A NOK 4B share buyback was announced, and raw material costs are expected to stabilize in 2025.
Orkla ASA Earnings Call Transcript: Q2 2025
Organic growth reached 3.8% with strong performance in Fuel Ingredients and Home & Personal Care, while Health and Snacks faced margin pressures from high input costs. Portfolio simplification and a potential India IPO progressed, with EBIT margin and return on capital employed both improving.
Orkla ASA Transcript: Capital Markets Update 2025
Delivered strong TSR and financial improvements, reduced portfolio complexity, and advanced strategic priorities for organic growth, simplification, and targeted M&A. Portfolio companies are on track for 2026 targets, with operational enhancements and ESG progress supporting long-term value creation.
Orkla ASA Earnings Call Transcript: Q1 2025
Solid quarterly results with 2% revenue growth, 10% EBIT (adjusted) increase, and 19% higher EPS year-over-year. Margin improvements were broad-based, though snacks and foods faced volume declines due to high cocoa prices and inventory adjustments. Portfolio simplification and cost-saving initiatives continued.
Orkla ASA Earnings Call Transcript: Q4 2024
Strong EBIT and cash flow growth in 2024, driven by portfolio simplification, margin improvements, and stable market shares. Cocoa price volatility and asset sales shaped the quarter, with a proposed NOK 10 per share dividend reflecting robust performance.
Orkla ASA Earnings Call Transcript: Q3 2024
Q3 delivered strong profit and margin growth, with adjusted EPS up 10% and EBIT up 17% year-over-year. Organic growth was broad-based, cash flow improved, and key segments like Jotun and Orkla Health outperformed, despite inflation and cocoa price pressures.
Orkla ASA Earnings Call Transcript: Q2 2024
Q2 saw 7% EPS growth and 13% EBIT Adjusted growth, with strong margin expansion and positive volume trends across most segments. Portfolio simplification advanced with asset sales, while input costs and private label competition remain key watchpoints.